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The outcome of a viral infection is regulated in part by the complex coordination of viral and host
interactions that compete for the control and optimization of virus replication. Severe acute respiratory
syndrome coronavirus (SARS-CoV) intimately engages and regulates the host innate immune responses during
infection. Using a novel interferon (IFN) antagonism screen, we show that the SARS-CoV proteome contains
several replicase, structural, and accessory proteins that antagonize the IFN pathway. In this study, we focus
on the SARS-CoV papain-like protease (PLP), which engages and antagonizes the IFN induction and NF-B
signaling pathways. PLP blocks these pathways by affecting activation of the important signaling proteins in
each pathway, IRF3 and NF-B. We also show that the ubiquitin-like domain of PLP is necessary for pathway
antagonism but not sufficient by itself to block these pathways regardless of the enzymatic activity of the
protease. The potential mechanism of PLP antagonism and its role in pathogenesis are discussed.
The outcome of a viral infection is mediated, in part,
through the complex interplay of viral and cellular components
that coordinate the innate immune response. During virus
entry and replication, the innate immune response machinery
senses the invading virus and activates a cascade of signaling
pathways that ultimately concludes with the translation of sev-
eral hundred antiviral proteins to convert the intracellular en-
vironment into a suboptimal context for replication (32). In
response to this powerful selective environment, viruses have
evolved strategies to disable the host’s innate immune arsenal
and optimize the intracellular environment for efficient virus
replication and release. Screens for interferon (IFN) antago-
nist activity of various viruses have shown that most viruses,
including all highly pathogenic human viruses tested, attempt
to modulate the innate immune response early in infection
(25).
The innate immune response is a series of signaling cascades
that are activated once a foreign pathogen is detected in the
host (34, 45). The response is initiated by cytoplasmic protein
sensors, such as RIG-I (retinoic acid-inducible gene I) and
MDA5, which bind to by-products of viral entry and replication
in the cell (2, 28, 51, 59). During viral infection, RIG-I and
MDA5 bind to viral single-stranded RNA and/or double-
stranded RNA (dsRNA) and signal through a protein called
MAVS (mitochondrial antiviral signaling protein) (51, 59).
MAVS activation leads to the activation of IKKi and TBK1,
the kinases which phosphorylate IRF3 to induce its dimeriza-
tion and import into the nucleus (34). Once phosphorylated by
the kinases, IRF3 dimerizes and is imported into the nucleus.
Nuclear IRF3, in complex with several other proteins, induces
type I IFN to alert neighboring cells of the infection. Once
IRF3 induces transcription of IFN-, this powerful cytokine is
secreted from the cells. The NF-B pathway is also activated
via these mediators as well. Homologous to the IRF3 signaling
pathway, kinases play a key role in activating the NF-B path-
way as well. The IKK, IKK, and IKK kinases phosphory-
late the NF-B inhibitor I. After I is phosphorylated,
it is targeted for degradation, which allows NF-B to be im-
ported into the nucleus. There it induces IFN- and complexes
with IRF3 to induce antiviral genes. The STAT1 signaling
pathways are activated via the binding of type I (IFN-), II
(IFN-), and III (IFN-) IFN binding to their receptors on the
surface of cells. This binding initiates either the formation of
the STAT1/STAT2/IRF9 complex (called ISGF3) after type I
or type III binding or STAT1 homodimerization after type II
IFN binding to receptors. STAT1 complex formation leads to
its import into the nucleus and activation of antiviral genes.
The regulation of these signaling cascades is crucially impor-
tant for the survival of the host. Disregulation of these events
can lead to increased infection and disease.
Many viruses encode proteins that block, modulate, or slow
several important signaling pathways that are involved in in-
duction or amplification of the innate immune response (3, 7,
10, 19, 35, 37, 38, 49, 55, 56). The Ebola virus encodes the
VP35 and VP24 proteins that block the dsRNA sensing and
STAT1 signaling pathways, respectively (7, 43). Coxsackievirus
B3 encodes the 3a protein, which blocks almost total protein
secretion during infection (9). The severe acute respiratory
syndrome coronavirus (SARS-CoV) encodes several innate
immune antagonists, including the open reading frame 6 (ORF6)
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protein, nucleocapsid, ORF3b, and nonstructural protein 1
(NSP1), which collectively antagonize the IRF3, JAK/STAT,
and/or NF-B signaling pathway (18, 29, 53). Although each
pathogen targets similar signaling pathways, they antagonize
host communication networks by different mechanisms using
distinctly different viral proteins.
SARS is an often fatal disease which emerged from China
during the fall of 2002 (15, 30). The disease quickly spread
across Asia, Europe, and North America. At the resolution of
the outbreak, more than 8,000 people had been infected, re-
sulting in 800 deaths and economic losses in the tens of
billions worldwide (23). The disease was caused by a new
human CoV (HCoV), named the SARS-CoV (21). The virus
likely originated from bats, as bat CoVs are pervasive, and
several are close relatives of the SARS-CoV in humans and
civets (31, 39). Thus, resurgence of SARS from zoonotic
sources remains a distinct possibility, making further under-
standing of the mechanisms regulating pathogenesis and viru-
lence of high significance (14, 54).
A previous report demonstrated that the papain-like pro-
tease (PLP) of the SARS-CoV is an IFN antagonist (13). PLP
was shown to block phosphorylation and activation of IRF3,
thereby antagonizing IFN- induction. Mechanistically, a di-
rect interaction between PLP and IRF3 was hypothesized to
sterically hinder the activation of IRF3. Finally, it was also
reported that PLP did not antagonize the NF-B signaling
pathway and that mutations in the catalytic site of PLP did not
affect its antagonism.
In this work, we develop a novel IFN antagonist screen to
identify several new potential IFN antagonists encoded in the
SARS-CoV genome and then focus on the mechanism of ac-
tion of one of them, PLP. In contrast to the studies detailed
above, we will show through in vivo expression studies and
biochemical studies involving purified proteins that PLP does
not directly bind to IRF3 or perturb the phosphorylation of
IRF3 by kinases and that PLP blocks the NF-B signaling
pathway via stabilization of the NF-B inhibitor, IB. Finally,
our work identifies a role for the active site of PLP and estab-
lishes that the ubiquitin-like (UBL) domain of PLP is neces-
sary, but not sufficient, for antagonism of IRF3 function. Im-
portantly, deletion of the PLP UBL domain did not alter
intrinsic proteolytic or deubiquitinating (DUB) activities. Fi-
nally, the HCoV-NL63 virus but not mouse hepatitis virus
(MHV) PLP was able to block IRF3 and NF-B signaling,
demonstrating strain-specific variation among members of the
family Coronaviridae.
MATERIALS AND METHODS
Cloning of SARS-CoV ORFs into VRPs. SARS-CoV ORFs were PCR ampli-
fied from the SARS-CoV molecular clone (57) and inserted into the Venezuelan
equine encephalitis (VEE) plasmid VR21 downstream of the 26S promoter by
overlap PCR (4). For most replicase proteins, an ATG start codon was added at
the N terminus of each coding region and a stop codon was added at the
C-terminus. Briefly, PCRs were performed with Expand Long Taq (Roche Mo-
lecular Biochemicals) in 30 cycles of 94°C for 30 s, 55°C for 30 s, and extensions
at 68°C for 1 min. The initial amplicon, which was used in the construction of all
of the constructs, was generated with primers 5	nsp4Sw (5	-GATTGAGGCGG
CTTTCGGCG) and 3	26S (5	-TTAATTAAGTCAATCGGCGCGCCCTTGGC
GGACTAGACTATGTC) using pVR21 as a template. The second amplicon was
made using the primers shown in Table 1 that flanked the SARS-CoV cistron of
interest and which included overlap sequences with the 3	26S primer. These
amplicons were then fused together by overlap PCR with the forward 5	NSL4sw
primer and the reverse primer for each ORF to produce a single amplicon and
then cloned into VR21 using the digestion scheme described above.
Expression plasmids. ORFs were cloned into the CAGGS/GFP (green fluo-
rescent protein) or CAGGS/HA (hemagglutinin) vector for expression in
HEK293T cells as previously described by our group (29). Amplicons were
produced using the primers shown in Table 1. For each construct, an ATG start
codon was added as the first codon but no stop codon was included at the 3	
terminus of each ORF. Rather, an HA or GFP tag was fused in frame to each
ORF. The amplicons and vector were digested with EcoRI/XmaI fragments for
cloning, and all constructs were verified by sequence analysis. Expression of each
plasmid was checked by Western blotting with either anti-HA (Sigma H3663) or
anti-GFP (Clontech 632459) antibodies after expression in 293T cells for 24 h.
Antibodies. For all Western blot experiments, anti-HA (Sigma H3663), anti-
GFP (Clontech 632459), anti-V5 (Invitrogen R960), antiactin (Santa Cruz I-19),
and anti-Flag (Sigma F7425) were used. Phospho-specific anti-IRF3 antibody
was provided by John Hiscott. To test VEE replicon particle (VRP) expression
of SARS-CoV proteins, antibodies were generated from mice in our laboratory.
VRPs expressing each protein were inoculated in the footpad. At 2 weeks after
inoculation, mice were boosted with the same VRP. At 4 weeks after the boost,
mice were bled and serum was collected for use in these assays. For Western
blots, serum was precleared by incubation of 25 
l of serum on a monolayer of
MA104 cells in a single well of a 24-well plate. At 2 h after incubation, serum was
removed from the well and used for Western blotting at a concentration of 1:500.
This procedure was used for all antibodies shown in Fig. S1 in the supplemental
material, with the exception of anti-NSP5 and anti-E. Anti-NSP5 antibodies were
used directly without preclearance, and anti-E antibody was kindly provided by
Luis Enjuanes.
IFN bioassay and IFN- RT-PCR. MA104 cells were infected with infectious
clone SARS (icSARS) or Sendai virus (SeV) at a multiplicity of infection (MOI)
of 5. Medium was removed from the cells for type I IFN bioassay, and intracel-
lular RNA was extracted from the cultures with Trizol at different times postin-
fection. The bioassay has been described previously for use with human type I
IFN and in A549 cells, and the methods were described more fully by Shabman
et al. (48). Briefly, the pH of the medium was lowered to 2 with 2 N HCl and
incubated at 4°C overnight to kill the activity of any other IFNs and chemokines
which may alter affects of the assay. IFNs are very stable at low pH, while other
proteins will be denatured. The pH of the medium was then adjusted to pH 7
with NaOH. One hundred microliters of the medium was then added to each well
of a 96-well plate containing A549 cells and incubated for 24 h. Encephalomyo-
carditis virus was then added at an MOI of 5, and the cultures were incubated for
24 h before scoring the plates for cytopathic effect (CPE). CPE was scored by
comparing medium-treated cells to a standard curve of IFN--treated cells.
Intracellular RNA was converted to cDNA with Superscript II (Invitrogen,
Carlsbad, CA) using random hexamers for cDNA synthesis, and the products
were then used for a reverse transcription-PCR (RT-PCR) using primer pairs
specific for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and IFN-.
The GAPDH-specific primers were 5	 GTCTTCACCACCATGGAGAAGGCT
GGGGCT 3	 and 5	 ACAGCCTTGGCAGCGCCAGTAGAGGCAGGG 3	,
while the IFN- primers were 5	 GACGCCGCATTGACCATCTA 3	 and 5	
CCTTAGGATTTCCACTCTGACT 3	, respectively.
Immunoprecipitations. HA- and Flag-tagged plasmids were transfected into
293T cells as described below. After 24 h of expression, cells were treated with
lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40), the extract was
centrifuged at 13,200 rpm for 10 min at 4°C, and the supernatant was removed.
EZ View Red anti-Flag M2 affinity gel beads (F2426; Sigma, St. Louis, MO) were
washed three times in 500 
l of lysis buffer per 100 
l of beads, and 25 
l of
washed beads was added to 100 
l of protein extract and rotated overnight at
4°C. For HA immunoprecipitations, protein G Dynabeads (Invitrogen) were
mixed with mouse monoclonal anti-HA antibody for 2 h on a rotating wheel at
4°C. After incubation, the bead-antibody mixture was washed three times with
lysis buffer and used for further immunoprecipitations. Twenty-five microliters of
protein G/HA antibody-treated beads was used for each immunoprecipitation.
One hundred microliters of protein extract was mixed with 100 
l of protein
extract and rotated overnight at 4°C. The mixture was then washed three times
with lysis buffer at 4°C. The protein extract-bead mixture was then resuspended
in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) load-
ing buffer before boiling and electrophoresis. For V5 immunoprecipitations, an
identical procedure to HA immunoprecipitations was used with the exception
that anti-V5 antibody (Invitrogen R960) was used in place of anti-HA.
Luciferase assays. To analyze the induction of IFN-- or NF-B-induced
genes, a luciferase reporter assay was used in 293T cells. Briefly, an expression
construct containing the luciferase ORF and either the IFN- promoter (IFN-
/luciferase) or a promoter containing three copies of the NF-B binding site
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(NF-B luciferase) was cotransfected with either a GFP control plasmid or the
designated PLP plasmid. Additionally, all transfections contained a plasmid
encoding Renilla luciferase under the control of the constitutive SV40 promoter
(SV40/Renilla luciferase). Transfections of reporter plasmids into 293T cells
were performed with the Fugene6 transfection reagent as directed by the man-
ufacturer (Roche). Twenty-four hours posttransfection, the cells were lysed and
assayed for luciferase expression using the Dual-Glo luciferase reagent (Pro-
mega) per the manufacturer’s instructions using a luminometer. The resulting
readout was analyzed by dividing the firefly luciferase induction under each
condition by the Renilla luciferase expression in each well. This controls for
transfection variation from well to well. The ratio of experimental to mock
treatment is graphed in each figure. Lysates were also assayed by Western
blotting for expression of the transfected proteins (see the supplemental mate-
rial). All three wells of each triplicate experiment were combined, and 10 
l of
the resulting lysates was analyzed by Western blotting with the designated anti-
bodies.
IRF3173–426, IRF31–426, and PLP purifications. Four liters of Escherichia coli
BL21(DE3) cells (Novagen) containing plasmid pGEX6P-1-IRF3173–426 was
grown in LB supplemented with 50 
g/ml of carbenicillin at 25°C to an optical
density at 600 nm of 0.6. To induce expression, the cultures were treated with
IPTG (isopropyl--D-thiogalactopyranoside) to a final concentration of 0.6 mM
and then grown for an additional 4 h under the above conditions. Cells were
pelleted by centrifugation (3,800  g, 30 min, 4°C) and resuspended in 100 ml
phosphate-buffered saline (PBS) supplemented with 2 mg DNase I, 5 mg ly-
TABLE 1. Primers and plasmids used in this study
Primer or plasmid
Sequence
Forwarda Reverse
VEE primers
ORF3a GTCTAGTCCGCCAAGATGGATTTGTTTATG
AGAT
GATCGGCGCGCCTTACAAAGGCACGCTAGTA
GTCG
ORF6 GTCTAGTCCGCCAAGATGTTTCATCTTGTT
GACT
GATCGGCGCGCCTTATGGATAATCTAACTCC
ATAG
ORF8b GTCTAGTCCGCCAAGATGTGCTTGAAGATC
CTTG
GATCGGCGCGCCTTAATTTGTTCGTTTATTT
AAAA
Spike GTCTAGTCCGCCAAGATGTTTATTTTCTTA
TTAT
GATCGGCGCGCCTTATGTGTAATGTAATTTG
ACAC
N GTCTAGTCCGCCAAGATGTCTGATAATGGA
CCCC
GATCGGCGCGCCTTATGCCTGAGTTGAATCA
GCAG
Bat ORF6 GTCTAGTCCGCCAAGATGTTTCATCTAGTT
GACT
GATCGGCGCGCCTTATGGATAATCTAACTC
CATA
NS1 GTCTAGTCCGCCAAGATGATGGATCCAAACA
CTGT
GATCGGCGCGCCTCAAACTTCTGACCTAATTG
TTCC
NSP1 GTCTAGTCCGCCAAGATGGAGAGCCTTGTTC
TTGG
GATCGGCGCGCCTTAACCTCCATTGAGCTCA
CGAG
NSP5 GTCTAGTCCGCCAAGATGAGTGGTTTTAGGA
AAAT
GATCGGCGCGCCTTATTGGAAGGTAACACCA
GAGC
NSP7 GTCTAGTCCGCCAAGATGTCTAAAATGTCTG
ACGT
GATCGGCGCGCCTTACTGAAGAGTAGCACGG
TTAT
NSP8 GTCTAGTCCGCCAAGATGGCTATTGCTTCAG
AATT
GATCGGCGCGCCTTACTGTAGTTTAACAGCT
GAGT
NSP10 GTCTAGTCCGCCAAGATGGCTGGAAATGCTA
CAGA
GATCGGCGCGCCTTACTGCATCAAGGGTTCG
CGGA
NSP12 GTCTAGTCCGCCAAGATGAGGCTGTAGGTGC
TTGT
GATCGGCGCGCCTTATTGTAATGTAGCCACA
TTGC
NSP15 GTCTAGTCCGCCAAGATGAGTTTAGAAAATG
TGGC
GATCGGCGCGCCTTATTGTAGTTTTGGGTAG
AAGG
NSP16 GTCTAGTCCGCCAAGATGGCAAGTCAAGCGT
GGCA
GATCGGCGCGCCTTATTAGTTGTTAACAAGA
ATAT
PLP GTCTAGTCCGCCAAGATGGGTGACAAAATTG
TGTAC
GATCGGCGCGCCTTACGACACAGGCTTGATG
GTTG
Expression plasmids
PLP WT GAATTCACCATGGAGGTTAAGACTATAAA
AGTG
CCCGGGCTTGATGGTTGTAGTGTAAGATGTT
TCCT
UBL only GAATTCACCATGGAGGTTAAGACTATAAA
AGTG
CCCCGGGTAGTACAAAGAAAGTCTTACCCTCA
PLPUBL GAATTCACCATGCCTAGTGATGACACACTAC
GTAGTGAAGCTTT
CCCCGGGTAGTACAAAGAAAGTCTTACCCTCA
MHV PLP1 GAATTCACCATGTCTATCTTGGATGAGCTTC
AAAC
ACTGCCCGGGCTTTTCAGCTATAGCACCTGCAA
CACCT
MHV PLP2 GAATTCACCATGTTGGATGATGATGCTCGTG
TCTTT
ACGTCCCGGGCGATAAATCTGGCTTATACTCCA
CACAC
NL63 PLP GAATTCACCATGGTTGTAGAGAGTAATGTTA
TGGAT
CCCGGGTGCACCAGTATCAAGTTTATCCATAA
CAGA
NSP2/3 cleavage GAATTCACCATGCAGTGTATACGTGGCAAGG
AGCAG
CCCGGGGTTGGTAAGGAGATCAGAAACTGGT
PLP W94A ACCACACAAAGAAAgcGAAATTTCCTCAAG
PLP C112A ATGGGCTGATAACAATgcaTATTTGTCTAG
PLP D287A CCCTCTATCGTATTGcCGGAGCTCACCTTA
a Added ATG start codons are underlined. Lowercase letters represent mutated bases.
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sozyme, and three Roche complete mini EDTA-free protease inhibitor cocktail
tablets. Cells were sonicated on ice using a 600-W model VCX ultrasonicator.
The cell debris was pelleted by centrifugation (40,900  g, 30 min, 4°C), and the
clarified cell lysate was loaded onto a 5-ml GSTrap column (GE Healthcare)
equilibrated with PBS and maintained at 4°C. Unbound protein was washed from
the column with a 10 column volume (CV) isocratic PBS wash. Protein was
eluted with 50 ml of elution buffer (50 mM Tris [pH 8.0], 15 mM glutathione).
Fractions containing glutathione-S-transferase (GST)-tagged IRF3173–426, as
judged by SDS-PAGE analysis, were pooled, concentrated, and exchanged into
cleavage buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol)
using 10-kDa molecular mass cutoff Millipore Centricon filter devices. The con-
centration of the 5-ml pool was determined by the Bradford assay, and 15 U of
PreScission protease (GE Healthcare) per mg of GST-IRF3173-426 was then
added to the pool and incubated for 16 h at 4°C. The cleaved protein sample was
diluted to 7 ml with PBS and loaded onto the GSTrap column, which was
equilibrated with PBS and maintained at 4°C. The column flow-through, ex-
pected to contain detagged IRF3, was collected and saved. The column was
washed with 12 ml of PBS, and the flow-through was again collected and saved.
All samples were analyzed by SDS-PAGE, and those containing detagged IRF3
were concentrated and exchanged into Mono-Q load buffer (20 mM Tris [pH
7.5], 10 mM -mercaptoethanol) using 10-kDa molecular mass cutoff Millipore
Centricon filter devices. The concentrated protein was loaded onto an 8-ml
Mono-Q 10/100 GL column (GE Healthcare) equilibrated with load buffer and
maintained at 4°C. Following loading of the column, unbound protein was
washed from the column with a 2 CV of load buffer. A 20 CV gradient from
0% to 100% Mono-Q elution buffer (20 mM Tris [pH 7.5], 250 mM NaCl) was
used to elute purified IRF3. Fractions containing IRF3173-426, as judged by
SDS-PAGE analysis, were pooled and concentrated to 1 mg/ml. Glycerol was
added to the protein to 10% (vol/vol). Aliquots of protein were frozen on dry ice
and then stored at 80°C.
IRF31-426 was purified in the same manner as IRF3173-426, with the exception
that Rosetta2(DE3)(pLysS) cells (Novagen) were used and LB was supple-
mented with 50 
g/ml of carbenicillin and 37 
g/ml of chloramphenicol. Ly-
sozyme was also eliminated from the lysis step.
For SARS-CoV PLP purification, the catalytic core of SARS-CoV PLP was
purified as previously described (6).
Native gel analysis. Native gel analysis consisted of incubation of various
amounts and combinations of proteins under native conditions and then analyz-
ing their migration by native PAGE. IKKi, IKK, and TBK1 kinases were
purchased from Invitrogen, while IB and NF-B (p50) were purchased from
Biomol International. Incubations generally consisted of 10- to 20-
l mixtures
containing 5 to 20 
g of each protein, alone or combined with another protein,
in 20 mM Tris (pH 7.5). Incubation mixtures were kept on ice for 10 to 15 min
before an equal volume of 2 native gel sample buffer (125 mM Tris [pH 6.8],
20% glycerol, 0.01 mg/ml bromophenol blue) was added. Typically, entire sam-
ples were loaded onto Tris-HCl 4 to 20% gradient or 10% acrylamide gels
equilibrated in running buffer (25 mM Tris, 190 mM glycine) at 4°C.
Cross-linking experiments. Proteins were cross-linked according to the pro-
tocol supplied with the bis(sulfosuccinimidyl)suberate (BS3) cross-linking re-
agent (Pierce). Prior to cross-linking, all proteins were dialyzed into buffer
containing 20 mM HEPES (pH 7.5) using Slide-A-Lyzer minidialysis tubes
(Pierce). In each dialysis tube, 100 
l of each purified protein was dialyzed into
1 liter of 20 mM HEPES (pH 7.5) for 2 h at 4°C with stirring in order to remove
Tris buffer, which would react with the cross-linking reagent. Each 30-
l cross-
linking reaction mixture contained 20 
M of each protein, either alone or with
another protein, and 1.5 mM freshly prepared BS3. Reaction mixtures were
incubated at room temperature for 35 min and then quenched with 1 
l of 1 M
Tris (pH 7.5) followed by an additional 15-min incubation. Ten microliters of 4
nonreducing SDS-PAGE sample buffer was added to each sample. Twenty mi-
croliters of each sample was then loaded onto a 12.5% SDS-PAGE gel.
IKKi and TBK1 phosphorylation of IRF3. Reactions to test the effect of
purified PLP on the phosphorylation of purified IRF3173–426 by IKKi (Invitro-
gen) were performed in 30-
l reaction mixtures at room temperature for 1 h.
Reaction mixtures contained 10 
g of purified IRF3173–426, 1 Z	-LYTE kinase
buffer (Invitrogen), 0.7 
g of IKKi, 330 
M ATP, and 20 
g of PLP. One
reaction mixture lacked ATP and PLP, and another lacked PLP. Fifteen to 20 
l
of each reaction was analyzed by SDS-PAGE. The same experiment was per-
formed with 0.54 
g of TBK1 (Invitrogen) as the kinase. For native gel analysis,
10 
l of each sample was diluted with 10 
l of 2 native gel sample buffer, and
samples were run on a Tris-HCl 4 to 20% gradient gel under native conditions
as described above.
IKK phosphorylation of IB. Phosphorylation experiments were per-
formed as described above for IRF3, but with 6 
g of IB (Biomol) as the
substrate and 0.82 
g of IKK (Invitrogen) as the kinase.
RESULTS
VRP-based IFN antagonist screen. The Venezuelan equine
encephalitis virus (VEE), an alphavirus, has been engineered
to produce replication-deficient particles (called VRPs), which
encode a foreign transgene under the control of the endoge-
nous viral 26S subgenomic mRNA promoter (4). As VEE and
VRP vectors induce robust type I IFN responses following
infection (47, 52), expression of an IFN antagonist from the
26S promoter may downregulate VRP-induced IFN responses
in cell culture (1).
To test this hypothesis, we inserted several SARS-CoV
structural and nonstructural ORFs, accessory ORFs, and the
influenza virus NS1 genes into VEE vectors and isolated high-
titer VRPs. The VRPs expressed robust levels of each of the
SARS replicase, accessory, and structural proteins (see Fig. S1
in the supplemental material). Cultures of MA104 cells were
infected with each VRP, and the induction and secretion of
type I IFN were measured by IFN bioassay (Fig. 1A and B).
When analyzing the accessory ORFs of SARS-CoV for their
ability to block type I IFN expression, the data demonstrated
that SARS-CoV ORF6 protein, and to a lesser extent the N
protein, reduced the accumulation of IFN in the media of
infected cells, along with NS1 of influenza virus, a known IFN
antagonist (20) (Fig. 1A). Additionally, we were able to assay
for IFN- mRNA induction by RT-PCR. Concordant with the
reported literature, the influenza virus NS1 gene blocked in-
duction of IFN-mRNA during VRP infection but ORF6- and
N-expressing VRPs did not. While the RT-PCR assay is not
quantitative, VRP/NS1-infected cells show a clear lack of
IFN- mRNA by RT-PCR while VRP/ORF6-infected cells
show a clear presence of IFN- mRNA. We have previously
shown that ORF6 protein antagonizes STAT1 signaling by
blocking STAT1’s nuclear import, and several groups have
implicated the CoV N protein as an antagonist as well, sup-
porting the robustness of this assay (18, 29, 56).
To determine whether the IFN bioassay was measuring the
accumulation of type I IFN that was amplified via the JAK/
STAT pathway or just the initially IRF3-induced IFN- being
secreted from the cell, we isolated mouse embryonic fibroblasts
(MEFs) from IFN-/ receptor-knockout (IFNAR/) mice.
VRPs expressing GFP efficiently induced the secretion of
IFN- in wild-type MEFs (Fig. 1C and D). In contrast, infec-
tion of IFNAR/ MEFs induced IFN- mRNA synthesis but
did not accumulate significant amounts of IFN- in the media,
as measured by bioassay. These data demonstrate that the
VRP-based IFN bioassay screen provides an effective IFN-
amplification pathway for the detection of IFN antagonists.
Identification of SARS-CoV replicase protein IFN antago-
nists. The VRP IFN antagonism assay identified ORF6 and N
as IFN antagonists, consonant with previous reports indicating
their role in IFN antagonism (18, 29). Next, the VRP system
was used to screen the NSPs (also called replicase proteins)
encoded in SARS-CoV ORF1a and ORF1b for IFN antago-
nism activity. While several NSPs were unable to be stably
cloned into VRPs either due to their large size (NSP3) or
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inherent instability (NSP4, -13, and -14); NSP1, NSP2, NSP5,
NSP6 to -12, NSP15, and NSP16 were efficiently cloned and
expressed from VRP-infected MA104 cells (see Fig. S1 in the
supplemental material). However, VRPs expressing NSP2,
NSP9, ORF3b, ORF7a, and M were also stable, but none
demonstrated IFN antagonist ability in these assays. However,
transgene expression could not be shown due to inadequate
antibodies for Western blot analyses and has been excluded
from the analysis. In VRP-infected MA104 cells, the IFN bio-
assay identified NSP1, NSP7, NSP15, and the PLP domain of
NSP3 as probable IFN antagonists. Interestingly, NSP1, NSP15,
and PLP also effectively reduced IFN- mRNA induction,
while NSP7 expression induced normal levels of IFN- mRNA
(Fig. 1B). Previous studies using overexpression plasmids and
reporter assays had only implicated NSP1 and NSP3 as poten-
tial antagonists, demonstrating the ability of the VRP assay to
detect novel antagonist activities (53). These data suggest that
NSP1, NSP7, NSP15, and PLP may be SARS-CoV-encoded
IFN antagonists. NSP7 and NSP15 are currently being ana-
lyzed in our lab. Below we analyze the IFN antagonist prop-
erties of PLP.
SARS-CoV PLP blocks the IRF3 pathway. Previous groups
have reported conflicting results concerning the mechanism of
PLP antagonism of IFN expression (13, 53). Based on the VRP
assay, our data (Fig. 1B) supported these earlier findings that
had suggested that PLP was blocking the IRF3-based IFN
FIG. 1. VRP-based screen for IFN antagonists. (A) MA104 cells were infected with VRPs expressing the identified ORFs at an MOI of 5 for
24 h. Type I IFN was quantified from supernatant of the infections using a type I IFN bioassay. Shown is the average of three experiments, each
in triplicate. (B) RNA was isolated from the same infections as in panel A and used for RT-PCR of IFN- and GAPDH expression. (C) MEFs
from wild-type (WT) 129 mice and IFNAR/ mice were infected with the identified VRPs and analyzed by bioassay (C) and RT-PCR for IFN-
and GAPDH expression (D).
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induction pathway. Consequently, we determined whether PLP
affected IFN- promoter expression from an IFN-/luciferase
reporter plasmid, using dsRNA and SeV as inducers (Fig.
2A and B). Briefly, 293T cells were transfected with an IFN-
/luciferase reporter plasmid and either a GFP-encoding con-
trol plasmid or a plasmid expressing HA-tagged PLP or GFP-
tagged PLP, as well as a control plasmid expressing Renilla
luciferase under the SV40 promoter as a transfection control.
FIG. 2. SARS PLP is an IFN antagonist. (A) HA- and GFP-tagged PLP expression plasmids were transfected into 293T cells with an IFN-/luciferase
construct. At 24 h posttransfection, cells were infected with SeV for 6 h and then luciferase was assayed to quantitate the level of induction of IFN-
transcription. (B) Using the same assay as in panel A, poly(I-C) was used as the inducer of IFN- transcript. (C) To analyze whether PLP affected
JAK/STAT signaling, PLP was transfected into cells with an ISRE/luciferase plasmid and incubated for 24 h. At 24 h, cells were treated with IFN-
protein for 6 h and then assayed for the induction of the ISRE promoter. We do not see a block in Jak/STAT signaling. (D) To identify where in the
IFN- induction pathway PLP is acting, cells were transfected with the IFN-/luciferase reporter and plasmids containing either GFP, N-RIG, MAVS,
IKKi or IRF3. The level of induction of each was set at 100%. Each plasmid was also transfected with HA-tagged PLP. Note that PLP blocked induction
by each plasmid, signifying that PLP is not inhibiting signaling events upstream of IRF3. On the right, PLPUBL was used instead of PLP in the same
experiments. Note that PLPUBL does not inhibit any of the inducers. (E) The UBL of PLP was used by itself to see if it blocked IFN induction via
-RIG, MAVS, IKKi, or IRF3. The UBL of PLP does not block the induction of IFN- by these proteins. (F) Using the previously published (13) PLP
construct, we find that it does block induction of IFN- when each of the IRF3 signaling pathway proteins is expressed.
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At 24 h posttransfection, cells were retransfected with 2 
g
poly(I-C) per well (a mimic of dsRNA) or infected with SeV.
Six hours after treatment, the cultures were analyzed for the
amount of luciferase expressed from the IFN- promoter.
Equal amounts of lysates were also used for Western blotting
analysis to ensure equal expression for each transfection (see
Fig. S2A in the supplemental material). We found that GFP-
and HA-tagged PLP were able to inhibit poly(I-C)- or SeV-
induced IFN- induction. We do not believe that PLP expres-
sion is affecting SeV infection, since at 48 h postinfection,
SeV-infected wells are showing a CPE, while uninfected cul-
tures show no CPE. This demonstrates that SeV replicates to
comparable levels in the transfected and untransfected cells.
Using a V5-tagged plasmid (PLP Sol) identical to that used by
Devaraj et al. (13), we found that these plasmids act the same
as the HA- and GFP-tagged PLP constructs. Equal amounts of
lysates were also used for Western blotting analysis to ensure
equal expression for each transfection (see Fig. S2B in the
supplemental material). Consonant with our earlier findings
and reports in the literature (13), PLP expression blocked
poly(I-C) and SeV induction of gene expression from the
IFN- promoter (Fig. 2A and B).
PLP lacks activity against the JAK/STAT1 pathway. To de-
termine whether PLP blocked the JAK/STAT pathway, which
is activated following the IFN- interaction via the IFN-/
receptor, we used a plasmid containing the IFN-stimulatable
response element (ISRE) promoter element fused to the firefly
luciferase ORF (ISRE/luciferase). Treatment of cells with
IFN- protein induces strong expression of luciferase in cells
transfected with the ISRE/luciferase construct. At 24 h after
cotransfection of PLP with the ISRE/luciferase plasmid, cells
were treated with IFN- for 6 h, which induced robust expres-
sion of luciferase in the presence or absence of PLP (Fig. 2C).
Equal amounts of lysates were also used for Western blotting
analysis to ensure equal expression for each transfection (see
Fig. S2C in the supplemental material). These data demon-
strate that PLP does not affect the JAK/STAT pathway.
PLP blocks IRF3 activation. To identify the cellular targets
associated with PLP antagonism, we analyzed whether PLP
was inhibiting the IRF3 activation pathway (Fig. 2D). Individ-
ual components of the IRF3 signaling pathway (RIG-I, MAVS,
IKKi, and IRF3) can be used to stimulate IFN- gene induc-
tion. The overexpression of each induces IFN-, and by using
an IFN-/luciferase plasmid as a reporter, we can assay
changes in the induction of IFN-. When plasmids expressing
the IRF3 pathway components N-RIG, MAVS, IKKi, and
IRF3 are transfected into cells, IFN- transcription was in-
duced (left third of Fig. 2D). Next, 293T cells were cotrans-
fected with plasmids expressing N-RIG, MAVS, IKKi, or IRF3
with either a GFP-encoding control plasmid or an HA-tagged
PLP plasmid. In Fig. 2D, we demonstrate robust induction of
IFN- luciferase expression following cotransfection with GFP
control plasmid. In contrast, cotransfection of PLP with each
pathway component resulted in a dramatic reduction in IFN-
reporter gene expression. Equal amounts of lysates were also
used for Western blotting analysis to ensure equal expression
for each transfection (see Fig. S2D in the supplemental mate-
rial). These data suggest that PLP blocks the virus-sensing
pathway at the level of IRF3 activation and/or signaling to the
nucleus, in agreement with earlier reports (13).
PLP inhibits the phosphorylation of IRF3. Activation of
IRF3 is achieved by phosphorylation of IRF3 via the kinases
IKKi and TBK1 (17). To determine if PLP antagonizes IRF3
phosphorylation, we transfected a plasmid expressing the IKKi
kinase into 293T cells in both the presence and absence of
HA-tagged PLP. IKKi overexpression should phosphorylate
IRF3, leading to its activation, nuclear import, and the subse-
quent induction of IFN- transcription. As previously re-
ported, IKKi expression robustly phosphorylated IRF3, which
was visualized using a phospho-specific, IRF3 antibody as a
probe (Fig. 3A). Importantly, PLP expression blocked the
phosphorylation of IRF3 while having no effect on total IRF3
protein levels. These data suggest that PLP is targeting an
activity upstream of IRF3 that affects IRF3 phosphorylation.
PLP does not inhibit the in vitro phosphorylation of IRF3.
To determine if PLP interferes with the kinase activity of either
of the upstream kinases, IKKi or TBK1, their activities were
studied in an in vitro kinase assay using purified components.
Purified IRF3 and each kinase were incubated in the absence
and presence of purified PLP. SDS-PAGE analysis of the re-
action products revealed that both IKKi and TBK1 catalyze
robust phosphorylation of IRF3, as indicated by the more
slowly migrating bands of the IRF3 protein (Fig. 4A and B).
The presence of PLP in these reactions had little if any effect
on the level of phosphorylation, suggesting that PLP does not
directly antagonize the phosphorylation status of IRF3.
IRF3 and PLP do not directly interact. In contrast to our
findings noted above, a recent study reported that a direct
interaction between IRF3 and PLP was associated with a block
in phosphorylation of IRF3 by IKKi or TBK1 (13). To recon-
firm whether a direct interaction occurs within cells, a Flag-
tagged IRF3 construct and HA-tagged PLP were singly or
doubly expressed in 293T cells. After transfection, the protein
complexes were extracted in NP40-containing buffer and the
membrane fractions were removed. Supernatant was assayed
for both Flag-tagged IRF3 and HA-tagged PLP, and both
proteins were found to be robustly expressed in the transfected
cultures (Fig. 3C, input). Anti-Flag tag and anti-HA antibodies
were used in coimmunoprecipitation experiments to directly
evaluate an IRF3-PLP interaction. After coimmunoprecipita-
tion with either the anti-FLAG or anti-HA antibodies, West-
ern blotting of the immunoprecipitated proteins demonstrated
that IRF3 and PLP were not bound in complexes despite
robust levels of Flag-tagged IRF3 or HA-tagged PLP expres-
sion (Fig. 3C). Therefore, no IRF3/PLP complexes were de-
tected in these assays. To demonstrate that IRF3 coimmuno-
precipitation was possible under these extraction conditions,
HA-tagged and Flag-tagged IRF3 were either singly or dually
transfected into 293T cells. At 24 h posttransfection, cells were
transfected with poly(I-C) as for the previous transfections,
and 6 h later, lysates were harvested. Lysates were immu-
noprecipitated under conditions identical conditions to
those described for PLP and IRF3, and the resulting immu-
noprecipitated protein was analyzed by Western blotting
using anti-HA and anti-Flag antibodies (Fig. 3B). We found
that Flag-tagged IRF3 was able to successfully immunoprecipi-
tate HA-tagged IRF3 under these conditions, demonstrating
that the lack of IRF3/PLP binding is not due to experimental
or technical protocols. We also performed coimmunoprecipi-
tation with the exact plasmids used in the studies of Devaraj et
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FIG. 3. Mechanism of PLP inhibition. (A) The effect of PLP on the phosphorylation of IRF3 was assayed by Western blotting. 293T cells were
transfected with a plasmid expressing IKKi and either GFP, PLP, or PLPUBL for 24 h. Protein was analyzed by Western blotting with either anti-IRF3
antibody (IRF3) or anti-phospho-IRF3 antibody (P-IRF3). The arrows signify the specific bands in each lane, and the asterisk denotes a background
band from the phospho-IRF3 antibody. (B) HA-tagged IRF3 and GFP-tagged IRF3 were either singly transfected or cotransfected into 293T cells to test
for coimmunoprecipitation conditions. At 24 h posttransfection, 500 ng poly(I-C) was added for 6 h to induce IRF3 homodimerization and IFN-. Lanes
2 and 3 show input extract blotted with anti-HA (HA) or anti-GFP (GFP) antibodies. The lysates from cotransfected cultures were used for
immunoprecipitation with anti-HA antibody (HA IP). The resulting immunoprecipitation is shown in lane 4. Note that HA- and GFP-tagged IRF3 was
able to be immunoprecipitated with anti-HA antibody. (C) IRF3 and PLP were expressed either individually or together in 293T cells to identify if they
bound each other in the cell. HA-tagged PLP and Flag-tagged IRF3 were transfected, and the extracts were used in immunoprecipitation experiments.
In lanes 1 to 4, anti-HA antibody was used to immunoprecipitate the proteins. In lanes 5 to 8, anti-Flag antibody (FLAG) was used for immunopre-
cipitation, and in the right section of the gel, 5% of the input for the immunoprecipitation was run in lanes 9 to 12. The top panel was visualized with
anti-Flag antibody for the Western blot, and the bottom panel used anti-HA for the Western blot. M, mock transfection; P, PLP transfections only; I,
IRF3 transfections only; and I/P, IRF3 and PLP transfected together. (D) V5-tagged PLP from Devaraj et al. (13) was used in IRF3 immunoprecipi-
tations. Identical conditions were used as in panel B, but anti-V5 antibodies (V5) were used for the pull down of V5-tagged protein complexes. Lane
1 is mock-immunoprecipitated extract. Lane 2 is V5 PLP Sol alone, lane 3 is V5-PLP TM alone, lane 4 is V5-PLP Sol cotransfected with Flag-tagged
IRF3, and lane 5 is V5-PLP TM cotransfected with Flag-tagged IRF3. The top panel shows a Western blot of the immunoprecipitated extracts with
anti-V5 antibody (V5 IP), and the bottom panel is an identical Western blot with anti-Flag antibody. (E) Interactions between purified PLP and
IRF3173–416 (E) or IRF31–426 (F) are shown as analyzed by 10% native-PAGE gels run at 4°C at pH 8.5. Proteins were incubated in different ratios, as
indicated above the gels, for 10 min and then diluted with 2 sample buffer before being loaded onto the gels. Locations of the individual proteins are
indicated by arrows to the left of the gels. (G) Cross-linking experiments with the cross-linking agent BS3 were performed between purified PLP and the
two forms of purified IRF3. Following a 30-min incubation at room temperature in the presence of BS3, the protein mixtures were quenched and then
analyzed by SDS-PAGE. Arrows to the right of the gel indicate the locations of the three individual proteins incubated without other proteins. Molecular
mass marker (M) sizes are shown to the left of the gel in kDa.
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al. (13): V5-tagged cytoplasmic PLP and PLP containing the
normal downstream transmembrane domain (PLP TM). Using
the identical procedure described above, we immunoprecipi-
tated V5-tagged PLPs alone or cotransfected with Flag-tagged
IRF3. IRF3 was not coimmunoprecipitated with either PLP
(Fig. 3D). Therefore, our data do not support a direct inter-
action between PLP and IRF3 in the context of transfected
cells.
To probe the potential interaction of PLP and IRF3 using
purified components in vitro, PLP and two versions of human
IRF3, including a full-length protein (IRF31–426) and IRF3
protein lacking its DNA-binding domain (IRF3173–416), were
purified to homogeneity and then analyzed for a potential
intermolecular interactions by native gel electrophoresis. Nei-
ther the full-length nor truncated IRF3 proteins, at different
protein/protein molar ratios, formed a complex with PLP, as
no larger-molecular-mass bands were visible on the gel (Fig.
3E and F). To investigate the potential that a PLP/IRF3 com-
plex may be too weak to withstand native gel electrophoresis,
the proteins were incubated and then cross-linked with a re-
agent that covalently links lysine side chains that are in close
proximity. In the presence of cross-linker, both versions of
IRF3 cross-link with themselves, as they are known to form
dimers (Fig. 3G); however, no additional higher-order bands
representing a PLP/IRF3 complex were observed when PLP
was added to the incubation. Both the native gel and cross-
linking experiments corroborate our earlier finding that PLP is
not directly binding to IRF3.
PLP blocks NF-B induction. The NF-B pathway is an-
other important signaling cascade that regulates innate im-
mune responses. Similar to components in the IRF3 pathway,
phosphorylation plays a central role in the induction of NF-
B-induced genes. Because PLP was affecting the IRF3 path-
way by blocking phosphorylation, it was reasonable to deter-
mine if PLP similarly targeted the NF-B pathway. Therefore,
the NF-B reporter plasmid was transfected into 293T cells
with SV40/Renilla luciferase control plasmid, and the cells
were then treated with either SeV (MOI of 5), poly(I-C) (2

g), or tumor necrosis factor alpha (TNF-) (10 ng). As ex-
pected, these stimuli induced robust induction of the NF-B/
luciferase construct (Fig. 5A, B, and C). In contrast to earlier
reports (13), cotransfection with HA-tagged PLP plasmid re-
duced luciferase expression following SeV, poly(I-C), or TNF-
treatment. We tested the V5-tagged PLP plasmid (named PLP
Sol) used by Devaraj et al. (13) and demonstrated a similar block
in NF-B signaling (Fig. 5A, B, and C, PLP Sol lanes). Equal
amounts of lysates were also used for Western blotting analysis to
ensure equal expression for each transfection (see Fig. S3A, B,
and C in the supplemental material).
As both the IRF3 and NF-B pathways are dependent on
IKK kinase phosphorylation-based activation (26), PLP could
be inhibiting the IKK kinase family, which mediates Ikb phos-
phorylation. To test this hypothesis, 293T cells were trans-
fected with a GFP plasmid or SARS-CoV PLP and treated
with 10 ng of TNF- per well for the specified time points (Fig.
5D). Proteins were isolated and assayed by Western blotting
for Ib phosphorylation levels, using an Ib phospho-spe-
cific antibody. Ib phosphorylation decreased across the time
points in the control lanes transfected with a plasmid encoding
GFP (1–4), consonant with the expected proteasome degrada-
tion that occurs after phosphorylation (50). Under identical
conditions, PLP coexpression stabilized the levels of Ib
phosphorylation. We find that SARS-CoV PLP expression
FIG. 4. PLP does not inhibit the in vitro phosphorylation of IRF3. Purified IRF3173–416 was incubated with IKKi (A) and TBK1 (B) and ATP
to induce phosphorylation and then analyzed by SDS-PAGE. The same reactions were carried out in the presence of PLP to determine if PLP
interferes with IRF3 phosphorylation. Locations of nonphosphorylated IRF3, phosphorylated IRF3 (p-IRF3), PLP, IKKi, and TBK1 are indicated
by arrows or brackets to the right of the gels. Molecular mass marker (M) sizes are shown to the left of the gels in kDa.
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does not block Ib phosphorylation but in fact stabilizes IBa
protein levels by inhibiting its degradation.
PLP does not inhibit IB kinase function in vitro. To
examine if PLP interferes with IB phosphorylation in vitro,
purified IB was incubated with purified IKK and ATP in
both the absence and presence of PLP and then analyzed by
SDS-PAGE and native PAGE. IBwas successfully phosphor-
ylated, but the presence of PLP did not reduce the kinase
activity of IKK with its IB target (Fig. 6A). PLP does not
appear to physically interact with either IB or phosphory-
lated IB as judged by the native gel analysis (Fig. 6B, lanes
1 and 2).
To determine if PLP interacts with other components of
the NF-B pathway, PLP was incubated with either individ-
ual proteins or specific protein complexes associated with
the pathway. Samples were then analyzed by native PAGE
(Fig. 6B). PLP did not bind the NF-B(p50) subunit (lane
8), nor the NF-B(p50)/IB complex (lane 10), under con-
ditions in which a strong and expected association was noted
between NF-B(p50) and IB (Fig. 6B, lanes 7 and 9).
These data indicate that the conditions in native PAGE do
not interfere with the formation of an established complex.
No association between PLP and the IKK kinase was ob-
served either (Fig. 6B, lane 5). These in vitro data indicated
that PLP does not likely block NF-B signaling by inhibiting
IKK kinase function.
NL63 PLP2, but not MHV PLP2, acts as an IFN antagonist.
We next evaluated whether the IFN antagonism properties of
the SARS-CoV PLP was conserved across other CoVs. Both
MHV and HCoV-NL63 encode two PLPs, PLP1 and PLP2,
the latter of each being the protein most homologous to SARS-
CoV PLP2 and conserved across CoVs (24). To evaluate IFN
antagonist activity, 293T cells were transfected with the IFN-
reporter plasmid, SV40/Renilla luciferase control plasmid, the
constitutively active N-RIG construct, and either empty plas-
mid, MHV PLP1, MHV PLP2, or HCoV-NL63 PLP plasmid.
At 24 h posttransfection, cells were lysed and assayed for levels
of luciferase expression (Fig. 7). As shown in Fig. 2D, N-RIG-
transfected cells expressed large amounts of luciferase, starkly
contrasting the inhibition in expression noted following coex-
pression of N-RIG with SARS-CoV PLP. In contrast, cultures
cotransfected with N-RIG and either MHV PLP1 or PLP2 did
not block IFN- induction, nor did they block NF-B or
STAT1 signaling (Fig. 7A to C). Importantly, NL63 PLP was
able to block IFN- induction as well as NF-B signaling,
similar to results reported with the SARS-CoV PLP. Equal
amounts of lysates were also used for Western blotting analysis
to ensure equal expression for each transfection (see Fig. S4A
to C in the supplemental material). It is noted that MHV PLP1
expresses at a slightly lower level than to MHV PLP2 and
SARS PLP. These data suggest that the CoV PLPs differen-
tially antagonize the IFN pathway, although it is possible that
MHV PLP antagonism might require an appropriate confor-
mational presentation as part of NSP3.
UBL domain of PLP is necessary for the IFN antagonism
activity of PLP. The crystal structure of the SARS-CoV PLP
demonstrated two major domains: an N-terminal region con-
taining a UBL domain and a C-terminal region containing the
protease active site (42). To determine whether the UBL do-
main functioned in innate immune antagonism, we constructed
FIG. 5. PLP inhibits the NF-B signaling pathway. (A) 293T cells
were transfected with a 3xB/luciferase reporter plasmid that reports
NF-B-mediated gene induction. The reporter was transfected with
PLP, PLPUBL, or PLP-Sol-expressing plasmids (13). At 24 h after
transfection, cells were treated wither either SeV (MOI of 5) (A),
poly(I-C) (2 
g) (B), or TNF- (10 ng) (C). Note that both PLP and
PLP-Sol block NF-B-mediated gene induction, while PLPUBL does
not. (D) The effect of PLP on NF-B signaling was assayed by Western
blotting. 293T cells were transfected with GFP, PLP, PLPUBL, or
UBL alone for 24 h. At 24 h posttransfection, cells were treated with
10 ng of TNF- for 0, 15, 30, or 45 min and proteins were extracted at
those time points. Western blots were analyzed for either total IKb or
phospho-IKb. Below the blot is the numerical ratio of total IKb to
phospho-IKb as quantified by IPLAB.
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a UBL-deleted PLP mutant (PLPUBL) that lacked the N-
terminal 60 amino acids (aa) of PLP (aa 683 to 783 of NSP3 or
aa 1 to 60 of the PLP expressed in this work), based largely on
the domain segmentation represented in the crystal structure.
The PLPUBL mutant, but not wild-type PLP, failed to block
IFN- induction by overexpression of RIG, MAVS, IKKi, and
IRF3 (Fig. 2D). Moreover, PLPUBL was also unable to block
NF-B/luciferase induction (Fig. 5A, B, and C). Under iden-
tical conditions, wild-type PLP efficiently blocked IFN- and
NF-B induction (Fig. 2D and 5A, B, and C).
To determine if the lone UBL domain was an inhibitor of
IRF3, we repeated these assays expressing the 60-aa UBL
domain and found that it was unable to block RIG-, MAVS-,
IKKi-, or IRF3-mediated induction (Fig. 2E). One caveat to
these experiments is that when expressed alone, the UBL do-
main may not fold correctly. We do not think this is an issue
since UBL domains are globular structurally stable protein
folds, and this domain resembles wild-type ubiquitin by crystal
structure. However, the potential for misfolding is noted.
These data suggested that the UBL domain of PLP is necessary
for blocking IRF3 and NF-B signaling yet was not sufficient to
inhibit that signaling.
The UBL domain is not required for PLP protease activity.
As previous studies have implicated the PLP protease function
in IFN antagonism activity (13), we next determined whether
the UBL-deleted PLP (PLPUBL), retained functional pro-
tease activity. To test for protease function of PLPUBL, we
amplified a region of the SARS-CoV genome containing the
C-terminal 80 aa of NSP2 and the N-terminal 100 aa of NSP3,
spanning the NSP2/3 cleavage site that is normally proteolyti-
cally cleaved by PLP (Fig. 8A). The NSP2/3 peptide was fused
to GFP in frame and expressed from a constitutive promoter in
293T cells. The uncleaved NSP2/NSP3/GFP fusion protein had
the expected molecular mass of 46 kDa (Fig. 8B, lane 1) and
was processed by PLP into an 35-kDa product (with a C-
terminally tagged GFP) and an N-terminal 10-kDa product,
with the former product detectable by GFP antibodies. Impor-
tantly, PLPUBL is capable of processing the precursor into
the expected 35-kDa protein product, although the presence of
the residual 46-kDa precursor protein suggested a slight re-
duction in proteolytic activity. Thus, the PLPUBL retains its
ability to proteolytically process the target polyprotein. Impor-
tantly, both the SARS-CoV UBL domain and the MHV PLP1
and PLP2 proteins were also unable to cleave the precursor
protein, demonstrating the specificity of the reaction for the
substrate (Fig. 8B).
PLPUBL retains DUB activity. SARS-CoV PLP has been
shown to have a significant amount of DUB activity (5). One
explanation for PLPUBL losing its IFN antagonist activity is
that the deletion of the UBL may specifically disrupt the DUB
activity of PLP, which may be responsible for the IFN antag-
onism. To test this hypothesis, 293T cells were transfected with
a Flag-tagged ubiquitin plasmid and either a plasmid express-
ing GFP, HA-tagged wild-type PLP, or HA-tagged PLPUBL.
At 24 h posttransfection, cells were lysed and assayed by West-
ern blotting with an anti-Flag antibody for the levels of Flag-
tagged ubiquitin attached to proteins in the lysate (Fig. 8C, top
panel). Flag-tagged ubiquitin is efficiently utilized by the cel-
lular machinery and is conjugated to proteins in the cell, re-
sulting in a smear of ubiquitinated proteins (Fig. 8C, lane 2).
Following cotransfection with wild-type PLP plasmid and the
tagged ubiquitin construct, PLP efficiently cleaves ubiquitin
from normally ubiquitinated proteins. Importantly, PLPUBL
also efficiently deubiquitinated proteins in the cell (Fig. 8C,
lane 4). Thus, DUB activity was also uncoupled from the mech-
anism by which PLPUBL failed to antagonize IFN activity.
DUB activity of PLP could be due to an artifact of plasmid
overexpression in cell culture. To exclude that possibility, we
analyzed the DUB activity of SARS-CoV and MHV during
virus infection. SARS-CoV DUB activity was analyzed by
transfection of Vero E6 cells with the same Flag-tagged ubiq-
uitin plasmid as before (Fig. 8D). At 24 h posttransfection,
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FIG. 6. Analysis of the effect of PLP on IB kinase activity and of PLP interactions with various NF-B pathway proteins. (A) IB was
incubated with IKK and ATP to induce phosphorylation and then analyzed by SDS-PAGE. The same reactions were carried out in the presence
of PLP to determine if PLP interferes with kinase activity. Locations of nonphosphorylated and phosphorylated IB, PLP, and IKK are indicated
by arrows. Molecular mass marker (M) sizes are shown to the right of the gel in kDa. (B) Native gel analysis of PLP interactions with NF-B
pathway proteins. Proteins were mixed, as indicated above the gels, and incubated in 50 mM HEPES (pH 7.5) for 10 min at 4°C and then diluted
with 2 sample buffer before being loaded onto the gels. Locations of the individual proteins are indicated by arrows to the left and right of the
gels.
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wild-type SARS-CoV (Urbani) was used to infect the cultures.
At 12 h after infection, the cells were lysed and used for
analysis by Western blotting. Similar experiments were per-
formed using MHV-A59 for the infection: however, in those
experiments, DBT cells were transfected with the Flag-tagged
ubiquitin plasmid (Fig. 8E). In both cases, we found that ubiq-
uitinated proteins are prevalent throughout uninfected cells.
However, virus infection is characterized by an almost com-
plete DUB of the cellular protein milieu. These data support
the hypothesis that the DUB activity seen from plasmid-based
expression of SARS-PLP is not an artifact of the expression
system. Additionally, they demonstrates that MHV-A59 deu-
biquitinates during the course of its infection in cell culture,
while its PLP2 does not seem to act as an antagonist in trans-
fection studies. This may suggest that DUB is not a critical
component of the IFN antagonism seen during infection or
that MHV PLP requires additional flanking sequences for in
vitro activity.
SARS-CoV PLP active site mutants show various degrees of
IFN antagonism. Since the PLPUBL mutant no longer
blocked IRF3 or NF-B signaling, we next determined whether
various protease active site mutations had an effect on PLP’s
IFN antagonism activity. The SARS-CoV PLP active site is
dependent upon a catalytic triad of amino acids, C1651,
H1812, and D1826 (42). We mutated the C1651 and D1826
catalytic residues to alanine and also mutated amino acid
W1633 of NSP3 to alanine, as this latter site likely blocks
proteolytic activity by altering the dimensions of the protease
pocket (42). When assayed in the presence of constitutive
RIG-I expression, the W1633A and D1826A mutations were
unable to block IFN- induction, whereas the C1651A mutant
retained near-wild-type activity in its IFN- inhibition activity
(Fig. 9A). To confirm levels of expression of the PLPs, West-
ern blot analysis was performed on these lysates and we found
that all PLPs are expressed at reasonable levels in the trans-
fections (see Fig. S4D and E in the supplemental material).
When assayed for their ability to block NF-B signaling,
none of the three mutants showed the ability to block TNF--
based induction of luciferase expression from the 3xB/lucif-
erase reporter plasmid (Fig. 9B). Interestingly, using the Flag-
tagged ubiquitin assay, the W1633A and D1826A mutations
allowed for robust DUB activity, while DUB activity was
greatly reduced with the C1651A mutation (Fig. 9D). In our
protease reporter assay, the W1633A and C1651A mutants lost
the ability to cleave the GFP reporter substrate while the
D1826A showed a reduction in proteolytic activity (Fig. 9C).
These data demonstrate that both the protease activity and the
UBL domain of PLP may play roles in IFN antagonism.
DISCUSSION
SARS-CoV is a highly pathogenic respiratory virus that
causes 50% mortality rates in aged populations. Although the
molecular basis for this highly virulent phenotype is unknown,
our findings build upon earlier reports that implicate the
SARS-CoV PLP as an IFN antagonist. Moreover, our novel
IFN antagonist assay also identified the SARS-CoV NSP1,
NSP7, NSP15, ORF6, and N protein as potential robust an-
tagonists of host innate immune signaling pathways. Previous
studies by our group and others have shown that NSP1 and
FIG. 7. PLP from NL63 but not MHV is an IFN antagonist. PLPs
from NL63 and MHV were assayed for their ability to inhibit IFN-,
NF-B, and STAT1 signaling in 293T cells. (A) In this assay, 293T cells
were transfected with N-RIG and either GFP-, MHV PLP1-, MHV
PLP2-, or NL63 PLP2-expressing plasmids and an IFN-/luciferase
reporter plasmid. At 24 h posttransfection, cells were assayed for
luciferase expression. The value of induction in GFP plus N-RIG was
set at 100%, with all other values in relation to it. Notice that MHV
PLP1 and -2 do not block IFN- induction, while NL63 and SARS-
CoV PLP do. (B) 293T cells were transfected with GFP-, MHV PLP1-,
MHV PLP2-, or NL63 PLP2-expressing plasmids and an NF-B/lucif-
erase reporter plasmid. At 24 h posttransfection, cells were treated
with 100 ng of TNF-; 6 h later, cells were assayed for luciferase
expression. The value of induction in GFP plus TNF- was set at
100%, with all other values in relation to it. Notice that MHV PLP1
and -2 do not block IFN- induction, while NL63 and SARS-CoV PLP
do. (C) 293T cells were transfected with either GFP-, MHV PLP1-,
MHV PLP2-, or NL63 PLP2-expressing plasmids and an ISRE/lucif-
erase reporter plasmid. At 24 h posttransfection, cells were treated
with 100 ng of IFN-; 6 h later, cells were assayed for luciferase
expression. The value of induction in GFP plus IFN was set at 100%,
with all other values in relation to it. Notice that none of the expressed
proteins inhibits ISRE induction.
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ORF6 block IFN induction and IFN signaling by diverse mech-
anisms (18, 29, 53). Here we demonstrate that SARS-CoV PLP
blocks the activation of IRF3 and NF-B and that the UBL
domain and catalytic site of PLP are necessary, but not suffi-
cient, to block IFN- and NF-B promoter induction.
IFN antagonist screen. VEE virus is a highly pathogenic
alphavirus that has been genetically manipulated as a vaccine
vector for the prevention of human and animal diseases (40).
The VEE replicon system produces VRPs which are replica-
tion defective, meaning they can infect a cell but do not pro-
duce progeny viruses from that cell. VRPs are high-titer (108
to 1010), single-hit particles that infect cells, replicate, and
produce large amounts of the foreign protein without spread-
ing beyond the initial target cell (11). Importantly VRPs in-
duce high levels of type I IFN from all cell types we have
tested, allowing for the detection of both IFN- mRNA and
type I IFN by bioassay. VRPs will efficiently infect (95% of
cells infected at an MOI of 5) mammalian, avian, and inverte-
brate cells, providing a screening platform for foreign genes
that encode IFN antagonism activities in diverse species. Some
A
B
C D E
FIG. 8. PLPUBL retains its protease and DUB functions. (A) A schematic of the SARS-CoV polyprotein cleavage assay is shown. The C
terminal 100 aa of NSP2 through the N-terminal 80 aa of NSP3 were fused to GFP in an expression plasmid. PLP should cleave between NSP2
and -3 at the black arrowhead if the PLP protease is functional. The uncleaved product should be 46 kDa (46kD), and the cleaved product should
be 35 kDa (35kD) when assayed on an SDS-PAGE gel. (B) 293T cells were transfected with either the cleavage reporter alone (mock) or the
reporter and each plasmid noted above the Western blot. Proteins were extracted 24 h posttransfection and analyzed by Western blotting with an
anti-GFP antibody to identify the cleaved or uncleaved cleavage reporter. The mock lane (lane 1) shows the full NSP2/3/GFP reporter. The PLP
lane shows the cleaved product at 35 kDa. (C) PLPUBL retains its DUB activity. 293T cells were transfected with Flag-tagged ubiquitin and
either GFP, PLP, or PLPUBL. Proteins were extracted 24 h posttransfection and analyzed by Western blotting (WB) with either an anti-HA
antibody (HA) (bottom panel) to visualize the PLP expression or anti-Flag antibody (FLAG) to visualize Flag-tagged ubiquitin (top panel).
(D) Vero cells were transfected with Flag-tagged ubiquitin and infected with icSARS-CoV at an MOI of 5 24 h posttransfection. Cells were lysed
at 12 h postinfection and assayed for anti-Flag and antiactin (ACTIN) staining by Western blotting. (E) BHK cells were transfected with
Flag-tagged ubiquitin and infected with MHV-A59 at an MOI of 5 24 h posttransfection. Cells were lysed at 6, 12, and 24 h postinfection and
assayed for anti-Flag and antiactin staining by Western blotting.
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advantages of the VRP screen include: (i) a large induction of
type I IFN, allowing for a high signal/noise ratio in the assays;
(ii) infection of virtually every cell in the culture; (iii) the
capablity of infecting cell types that are highly resistant to
transfection methodologies (e.g., MEFs derived from wild-type
and gene knockout mice); and (iv) expression of the query
gene in the context of virus infection rather than plasmid-based
overexpression. Importantly, expression of antagonists from
defective VRP vectors is safe since they do not spread in vitro
or in vivo. One caveat to using VRP vectors is that transgene
expression may potentially underrepresent or overrepresent
the expression levels seen in wild-type SARS-CoV-infected
cells. This potential problem is recognized and is why further
follow-up with plasmid- and wild-type virus-based expression is
used.
Wathelet et al. have evaluated the SARS ORF1ab NSPs for
IFN antagonist activity and identified NSP1 and NSP3, using
an SeV screen that coupled a plasmid-based antagonism ex-
pression with a luciferase-based readout for IFN induction
(53). In addition to NSP1 and NSP3, the VRP approach also
identified NSP7 and NSP15 as robust IFN antagonists. Again,
the differences may reflect inherent differences between plas-
mid-based and VRP-based screens and/or differences in the
innate levels of IFN induction associated with paramyxovirus
and alphavirus infection. The most comprehensive interpreta-
tion of these data suggests that (i) combinations of screens may
represent a better approach to identify potential candidates for
downstream testing and (ii) more detailed studies of antago-
nism mechanisms in different viral genome backbones may be
warranted.
IFN antagonists of SARS. Many viruses encode proteins that
block the innate immune response, and a detailed mechanistic
understanding of the process may lead to the identification of
therapeutic targets that can be used to attenuate replication
and pathogenesis. For example, influenza viruses containing
deletions of NS1, an IFN antagonist, are attenuated in vivo,
suggesting a precise antiviral target for therapeutics (41). We
have previously identified three SARS-CoV proteins, nucleo-
capsid, ORF3b, and ORF6, which antagonize host innate im-
mune responses and demonstrated that ORF6 binds nuclear
import factors to antagonize import of activated STAT1 (18,
29). Our finding, coupled with earlier reports, indicate that
several replicase proteins of SARS-CoV encode important
functions outside of a role in virus replication, suggesting an
important role for ORF1 proteins in virulence and pathogenic
disease outcomes that are uncoupled from virus load. Intrigu-
ingly, mutations in NSP1 (36, 53), NSP2 (22), and NSP14 (16)
have been shown to affect various aspects of in vitro and in vivo
FIG. 9. PLP catalytic mutants play a role in IFN antagonism. (A) 293T cells were transfected with an IFN-/luciferase plasmid that reports
IRF3-mediated gene induction. The reporter was cotransfected with N-RIG and GFP, PLP, or the PLP W1633A, C1651A, or D1826A mutants.
At 24 h after transfection, cells were lysed and assayed for luciferase expression. (B) 293T cells were transfected with a 3xB/luciferase plasmid
that reports NF-B-mediated gene induction. The reporter was cotransfected with GFP, PLP, or the PLP W1633A, C1651A, or D1826A mutants.
At 24 h after transfection, cells were treated with 10 ng of TNF-, and 6 h after treatment, the cells were lysed and assayed for luciferase expression.
(C) PLP mutants were tested for their cleavage activity using the construct and experimental design described in the legend to Fig. 8. The top panel
is a Western blot for anti-GFP showing cleavage of the reporter protein, and the lower panel is a Western blot of the same extract probed with
anti-HA antibody showing expression of the PLP mutants. (D) Deubiquitinase activities of the PLP mutants were assayed using the Flag-tagged
ubiquitin assay described in the legend to Fig. 8. The top panel is a Western blot probed with anti-Flag antibody showing Flag-ubiquitin conjugation
to cellular proteins. WT, wild type. The bottom panel is a Western blot with anti-HA antibody showing expression of the PLP variants.
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infections and pathogenesis, although the exact mechanisms of
their function is still under active investigation. Our findings
support earlier work by Wathelet et al. (53), who demonstrated
that NSP1 blocks several kinase, transcription, and translation
steps that are normally induced during viral infection. In par-
allel, Narayanan et al. showed that NSP1 affects IFN- gene
transcript stability which augments NSP1’s IFN antagonism
activity (36). While the mechanisms of action of NSP1 and PLP
have been well studied, the molecular mechanisms by which
NSP7 and NSP15 block various aspects of the antiviral re-
sponse are fertile ground for future investigations.
It is intriguing that SARS-CoV encodes at least seven IFN
antagonist genes. Although the basis for encoding such a large
repertoire of antagonists is unknown, poxviruses, paramyxovi-
ruses, and filoviruses encode multiple IFN antagonism genes as
well (28, 37, 44). Consistent with an important role for IFN in
regulating the severity of CoV infection, MHV infection of
IFN-/ and IFN- receptor knockout mice enhances disease
severity and rapidly progresses to fatal outcomes (8, 46). It has
also been shown that SARS-CoV infection of either cell cul-
ture (18) or of macaques (12) results in a block in STAT1
translocation to the nucleus, suggesting that control of the IFN
response is an important component in virus pathogenesis. It is
likely that viruses encode multiple IFN antagonists to retard
the induction of the innate immune responses during the early
phases of infection to allow for efficient replication and spread.
Alternatively, different antagonists may function more effi-
ciently in different tissues and host cells that are targeted
during infection.
PLP IFN antagonism. Devaraj et al. (13) identified the
SARS-CoV PLP as an IFN antagonist, implicating a direct
interaction with IRF3 as a mechanism that blocked phosphor-
ylation and nuclear import. In contrast, Wathelet et al. (53)
identified NSP3 as an IFN antagonist but did not attempt to
show an interaction directly with IRF3. In agreement with both
laboratories, we show that PLP is an IFN antagonist that
blocks the phosphorylation of IRF3 by a yet-to-be-identified
upstream mechanism. However, we do not detect a direct
IRF3-PLP interaction by immunoprecipitation assays using ei-
ther cell lysates or purified protein components in in vitro
biochemical assays. Additionally, a recent paper by Zheng et
al. identified MHV PLP2 as a IFN antagonist and showed a
direct interaction between IRF3 and PLP, both of which we
cannot repeat in our experiments (58). Zheng et al. propose
that the DUB activity of MHV PLP2 blocks IRF3 function,
leading to the block in IFN antagonism. One caveat to their
work is that PLP appears to nonspecifically deubiquitinate all
proteins in the cell, including IRF3 (Fig. 8C, D, and E). They
do not show this result in their paper, but we have demon-
strated this fact here. Thus the interpretation that IRF3 DUB
is solely critical for the IFN block is premature and not sub-
stantiated by the existing data. Devaraj et al. (13) also pre-
sented data showing that the catalytic activity of PLP was not
essential for the IFN antagonist activity, although one mutant
(C1651A) showed reduced activity compared with controls.
Using a broader panel of active site mutants, we present data
demonstrating that some of the mutants involving residues that
participate directly in catalysis, or residues within the catalytic
region of the active site, disrupt the IFN antagonism activity.
We also demonstrated a significant block in NF-B signaling
by PLP following stimulation with TNF-, SeV, or dsRNA, in
contrast to previous studies that assayed for antagonism of
NF-B signaling pathways by RT-PCR of the A20 message, an
NF-B-induced gene in some cell lines (13). The differences
between our observations may reflect the sensitivity of our
luciferase assay, the use of different cell types, or the differen-
tial induction of this particular A20 message via alternative
signaling pathways. Importantly, we demonstrate a block in the
NF-B signaling pathway using three different inducers of NF-
B, including SeV, the dsRNA mimic poly(I-C), and TNF-.
Regardless of the inducer, we find that PLP is able to block
NF-B-mediated signaling. We do note that these contradic-
tory findings certainly support the argument that multiple bio-
chemical assays and inducers should be used to record NF-B
and IFN antagonism activities, coupled with well-defined mu-
tants that display loss or gain of function.
Role of the UBL domain in IFN antagonism. We found that
the UBL domain of PLP was necessary but not sufficient for
PLP’s IFN antagonist activity. When the UBL was deleted
from PLP, the protease and DUB functions of PLP were re-
tained (Fig. 6). However, this form of PLP did not inhibit IRF3
phosphorylation or NF-B signaling. Interestingly, the UBL
domain alone was not able to inhibit these pathways either.
Although the mechanism is unclear, an interaction between
the UBL domain and the upstream effector proteins involved
in activation of the pathway is a strong possibility (27). TBK1,
IKKi, and IKK each contain UBL domains that are critical
for their enzymatic activity, and the removal of these UBL
domains has been shown to impair their function (27, 33).
Interestingly, enzymatic activity can be restored with UBL do-
mains derived from the reciprocal kinase, IKKi or TBK1. We
are intrigued that the kinases and PLP both contain UBL
domains, although we cannot show any direct involvement or
direct protein-protein interactions in vitro or in vivo.
Role of the catalytic domain in IFN antagonism. The cata-
lytic region of PLP plays a role in IFN antagonism as well.
Mutagenesis of the catalytic triad in the active site differentially
affected IFN antagonism (Fig. 9). We found that mutagenesis
of the active site at two different residues, which have been
shown to knock out catalytic activity (6), also affects the an-
tagonism activity. These data not only suggest that the catalytic
site activity may be directly involved in the IFN and NF-B
antagonism phenotypes, but alternatively, the mutations may
alter the PLP structure and, via long-range interactions, dis-
rupt IFN antagonism activities. This possibility is strengthened
by findings with the W1633A mutant, which loses IFN and
NF-B antagonism and protease activity but retains some
DUB activity. Based on analysis of the X-ray structure, the
W1633 residue is thought to be necessary for retention of the
correct active site architecture. Mutation of this site is pre-
dicted to lead to a potential collapse of the active site pocket
into a smaller pocket volume resulting from increased flexibil-
ity in the region created by the loss of a hydrogen bond. The
decreased size would lead to the inability of the pocket to
accommodate the larger leaving groups of the polyprotein but
would perhaps still allow for the smaller isopeptide bonds of
ubiquitin conjugates to bind, as observed in our assays. Al-
though speculative, the catalytic site of PLP may bind and/or
proteolytically degrade key cellular proteins that promote IFN
expression. Alternatively, the mutations in the catalytic site
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may be affecting protein structure such that the cellular pro-
teins interacting with wild-type PLP can no longer bind to the
mutant form. Further X-ray structural analysis of the interac-
tions with different substrates is warranted in order to tease out
any structural effects on molecular recognition and catalysis.
In conclusion, we have used a novel IFN antagonist assay to
identify NSP1, PLP, NSP7, NSP15, ORF6, and N as IFN
antagonists. These findings, coupled with the identification
of differential IFN antagonism activities encoded within dif-
ferent PLPs, suggest that Coronaviridae genomes likely encode
multiple and different antagonists of innate immunity. The
availability of a robust mouse model for studying the patho-
genesis of SARS-CoV enables us to evaluate the role of these
genes in pathogenesis. This allows for the ability to identify
novel antagonists both in vitro and in vivo and to understand
their mechanisms for evading the host innate immune re-
sponse. Understanding the mechanism of action of each an-
tagonist may also direct us to novel therapeutic targets on both
the virus and the host.
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